Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer
NCT06009510 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-08-24
Summary
The study seeks to delve into the firsthand experiences of patients diagnosed with bladder cancer who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.
By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future bladder cancer patients and play an active role in advancing medical research.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-30
- Primary Completion
- 2025-09-30
- Completion
- 2026-09-30
Countries
- United States
Study Locations
More Related Trials
-
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
NCT02735512 ·Status: TERMINATED
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429 ·Status: RECRUITING
-
The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations
NCT04900259 ·Status: COMPLETED
-
Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer
NCT06337305 ·Status: COMPLETED
-
Quality of Life in Patients With Bladder Cancer
NCT00745355 ·Status: ACTIVE_NOT_RECRUITING
-
Recovery Support for Bladder Cancer Patients and Caregivers
NCT04055311 ·Status: COMPLETED ·Phase: NA
-
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
NCT06586255 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
NCT00055601 ·Status: COMPLETED ·Phase: PHASE2
-
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
NCT00045630 ·Status: COMPLETED ·Phase: PHASE2
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
NCT07048496 ·Status: RECRUITING ·Phase: NA
-
Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer
NCT01840137 ·Status: COMPLETED ·Phase: NA
-
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
NCT03757949 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
NCT06350734 ·Status: ACTIVE_NOT_RECRUITING
-
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
NCT01373294 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003129 ·Status: COMPLETED ·Phase: PHASE2
-
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00014144 ·Status: COMPLETED ·Phase: PHASE2
-
Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
NCT06986304 ·Status: RECRUITING
-
Biological Therapy in Treating Patients With Bladder Cancer
NCT00003779 ·Status: COMPLETED ·Phase: PHASE3
-
Bio Clinical Collection of Urothelial Carcinoma
NCT04970472 ·Status: RECRUITING
-
Health-Related Quality of Life in Patients With Bladder Cancer
NCT00744744 ·Status: COMPLETED
-
Decision Making for Urinary Diversion in Patients With Bladder Cancer
NCT05111639 ·Status: COMPLETED
-
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
NCT07342517 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life
NCT05195515 ·Status: ENROLLING_BY_INVITATION